Mohammad Alomari, MD
Resident
Cleveland Clinic Foundation
Cleveland, Ohio
Mohammad Alomari, MD1, Ismail Hader, MD2, Laith Al Momani, MD3, Leen Nusairat, MD1, Bara El Kurdi, MD3, Shrouq Khazaaleh, MD4, Mark Young, MD3, Carlos Romero-Marrero, MD, MSc5
1Cleveland Clinic Foundation, Cleveland, OH; 2Beaumont Health, Royal Oak, MI; 3East Tennessee State University, Johnson City, TN; 4King Abdullah University Hospital, Ar Ramtha, Irbid, Jordan; 5Digestive Disease Institute, Cleveland Clinic Foundation, Cleveland, OH
Introduction: Hepatitis B and C are the main causes of liver failure worldwide. Drug use places people at particular risk for contracting viral hepatitis. Therefore, we conducted this study to evaluate the incidence rate and trend of these infections over fifteen successive years between 2002 and 2016 the united states.
Methods: This is a retrospective epidemiological study that included patients diagnosed with hepatitis B and hepatitis C from the National Inpatient Sample Registry between 2002-2016. We excluded those with missing information, age < 18 years old and hospital transfers based on the ICD-9 and 10 codes. (Figure 1) Data were then stratified based on drug use status. Poisson regression with robust estimator was used to assess the trend of drug use, as well as the association with age, sex, race, and region.
Results: A total of 9,475,105 hospitalizations with hepatitis B or C were included. Of them, 2,532,542 patients had a drug use diagnosis. The incidence of drug use in hepatitis increased from 22.7% (2002) to 30.6% (2016) (Figure 2), with an adjusted annual percent change of 3.4%. Male sex (PR 1.237,95% CI 1.234-1.240) and younger age (0.963, 0.963-0.963), were associated with higher drug use. Compared to the white race, the black race had a higher prevalence of drug use (1.143, 1.139-1.146), while Hispanics (0.981, 0.978-0.985) and other races (0.581, 0.577-0.584) were associated with lower drug use prevalence ratios. Furthermore, the highest drug use prevalence ratio was in the Northeast, followed by the West (0.820, 0.817-0.822), the Midwest 0.735 (0.732-0.738), and finally, the South (0.654, 0.652-0.656). (Table 1)
Discussion: Drug use in patients with hepatitis B and C is rising at an alarming rate in the United States. This emphasizes on the need for more efforts to combat drug use through known effective methods which will have a significant consequence on these individuals and, subsequently, our communities.
Citation: Mohammad Alomari, MD; Ismail Hader, MD; Laith Al Momani, MD; Leen Nusairat, MD; Bara El Kurdi, MD; Shrouq Khazaaleh, MD; Mark Young, MD; Carlos Romero-Marrero, MD, MSc. P0604 - NATIONAL TRENDS IN THE EPIDEMIOLOGY OF DRUG USE IN PATIENTS WITH HEPATITIS B AND C INFECTIONS. Program No. P0604. ACG 2019 Annual Scientific Meeting Abstracts. San Antonio, Texas: American College of Gastroenterology.